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Abstract
Background: Hutchinson-Gilford progeria syndrome (HGPS) is a premature ageing syndrome that affects children
leading to premature death, usually from heart infarction or strokes, making this syndrome similar to normative
ageing. HGPS is commonly caused by a mutation in the A-type lamin gene, LMNA (G608G). This leads to the
expression of an aberrant truncated lamin A protein, progerin. Progerin cannot be processed as wild-type pre-
lamin A and remains farnesylated, leading to its aberrant behavior during interphase and mitosis.
Farnesyltransferase inhibitors prevent the accumulation of farnesylated progerin, producing a less toxic protein.
Results: We have found that in proliferating fibroblasts derived from HGPS patients the nuclear location of
interphase chromosomes differs from control proliferating cells and mimics that of control quiescent fibroblasts,
with smaller chromosomes toward the nuclear interior and larger chromosomes toward the nuclear periphery. For
this study we have treated HGPS fibroblasts with farnesyltransferase inhibitors and analyzed the nuclear location of
individual chromosome territories. We have found that after exposure to farnesyltransferase inhibitors mis-localized
chromosome territories were restored to a nuclear position akin to chromosomes in proliferating control cells.
Furthermore, not only has this treatment afforded chromosomes to be repositioned but has also restored the
machinery that controls their rapid movement upon serum removal. This machinery contains nuclear myosin 1b,
whose distribution is also restored after farnesyltransferase inhibitor treatment of HGPS cells.
Conclusions: This study not only progresses the understanding of genome behavior in HGPS cells but
demonstrates that interphase chromosome movement requires processed lamin A.
Background
Hutchinson-Gilford progeria syndrome (HGPS) is an
extremely rare disorder that affects children causing
them to age prematurely [1]. Clinical features of this
disease include alopecia, growth retardation, an extre-
mely aged appearance, loss of subcutaneous fat, progres-
sive atherosclerosis, bone deformaties and cardiovascular
diseases [2-5]. HGPS is most frequently caused by an
autosomal dominant de novo mutation in the LMNA
gene, which encodes the nuclear intermediate filament
proteins lamin A and lamin C [6]. These A-type lamins
are both components of the nuclear lamina at the inner
nuclear envelope and of the nuclear matrix [7-10].
Lamin proteins have roles in DNA replication, transcrip-
tion, chromatin organization, maintenance of nuclear
shape and integrity and in cell division [11,12]. The
most common mutation associated with HGPS is a sin-
gle base substitution in codon 608 of exon 11 on the
LMNA gene resulting in the formation of a cryptic
splice site that produces a truncated pre-lamin A pro-
tein called progerin, lacking 50 amino acids near the
carboxyl terminus [6,13]. Progerin acts in a dominant
negative manner on the nuclear functions of cell types
that express lamin A, which comprise the majority of
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differentiated cells derived from mesenchymal stem cells
[14].
In normal cells, pre-lamin A contains a CaaX motif at
the carboxy-terminal end, where the cysteine residue
becomes farnesylated by the enzyme farnesyltransferase
[15]. The presence of a farnesyl group at the carboxy-
terminal end, along with the CaaX motif, promotes the
association of pre-lamin A with the nuclear membrane
and these are thus vital for correct localization of the
mature protein [16]. The protein undergoes an endo-
proteolytic cleavage by the enzyme ZMPSTE24-FACE1
metalloproteinase [17], resulting in the cleavage of 15
amino acids at the carboxy-terminal end, including the
farnesylated cysteine, producing mature lamin A [18]. In
HGPS, an activation of the cryptic splice site results in
an internal deletion of 50 amino acids near the carboxy-
terminal end of the protein, including the ZMPSTE24-
FACE1 cleavage site. This deletion does not affect the
CaaX motif and the progerin undergoes normal farnesy-
lation, but it lacks the ZMPSTE24-FACE1 recognition
site necessary for the final cleavage step and hence
remains farnesylated [13,19]. Retention of the farnesyl
group and accumulation of the farnesylated protein at
the nuclear envelope compromises nuclear integrity and
leads to formation of abnormally shaped nuclei, a pro-
minent characteristic seen in HGPS [20,21]. The con-
cept that blocking the farnesylation of progerin might
help ameliorate disease pathology seen in HGPS cells
was proposed in 2003, shortly after the discovery of the
gene involved in causing HGPS. Thus, drugs called far-
nesyltransferase inhibitors (FTIs), which inhibit attach-
ment of a farnesyl group to a protein by irreversibly
binding to the CaaX domain [22], were used in both in
vitro and in vivo analyzes. The lack of a progeria pheno-
type in a knock-in mouse model expressing non-farnesy-
latable progerin supports this approach [23].
In vitro studies have demonstrated that treating HGPS
cells with FTIs prevents the accumulation of progerin at
the nuclear envelope and reduces the frequency of
abnormally shaped nuclei in culture [3,24-27], reduces
nuclear blebbing as well as the redistribution of mutant
protein from the nuclear envelope [3], and restores gen-
ome localization after mitosis [28] and the distribution
of nucleolar proteins [29]. HGPS cells treated with FTIs
for 72 hours also showed improved nuclear stiffness to
levels almost comparable to normal cells and significant
restoration of directional persistence with regards to cell
migration and thus improvement in wound healing abil-
ity [30]. Another study demonstrated that double strand
break repair was improved in HGPS cells after FTI
treatment [31]. Treatment with FTIs has also been
employed in animal models with positive results. FTI
treatment of ZMPSTE24-/- mice resulted in the pre-
sence of non-farnesylated prelamin A, improved growth
curves, bone integrity and body weight [19], and a
reduction of rib fractures [27,32-34]. The study in Lmna
HG/+ mice demonstrated that FTI treatment improved
body weight and bone structure, with improvement in
bone mineralization and cortical thickness [32]. A more
recent study that uses a transgenic mouse model carry-
ing the human G608G LMNA mutation and displaying
a cardiovascular phenotype demonstrated that FTI treat-
ment reduces vascular smooth muscle cell loss and pro-
teoglycan accumulation and thus prevented the onset as
well as the progression of cardiovascular diseases in
these mice [35].
One of the shortcomings that FTI treatment has been
confronted with is that these drugs may cause an alter-
native post-translational modification of pre-lamin A or
progerin [36]. Pre-lamin A and progerin are both gera-
nylgeranylated by the enzyme geranylgeranyltransferase
when they are not permitted to undergo farnesylation in
the presence of FTIs [37]. Inhibition of both enzymes,
that is, farnesyltransferase and geranylgeranyltransferase,
using a FTI and a geranylgeranyltransferase inhibitor
(GGTI) simultaneously results in accumulation of sub-
stantially higher levels of normal pre-lamin A [37].
Thus, in the present study we have used both types of
drugs, FTIs and GGTIs, to inhibit progerin processing
in vitro.
Interphase chromosome territories are positioned non-
randomly in a radial pattern in nuclei, with gene-rich
chromosomes located towards the nuclear interior,
gene-poor chromosomes towards the nuclear periphery
and chromosomes carrying intermediate gene loads in
an intermediate position [38,39]. It has been demon-
strated that chromosome position is altered in cells that
leave the cell cycle reversibly into quiescence or irrever-
sibly into senescence [40-43] (IS Mehta, KJ Meaburn, M
Figgitt, IR Kill, JM Bridger, manuscript in preparation).
In addition, we have previously shown that interphase
radial chromosome positioning is altered in the nuclei
of proliferating human dermal fibroblasts (HDFs)
derived from patients diagnosed with different lamino-
pathies, including classical HGPS [41]. We revealed that
chromosomes 13 and 18, normally located at the
nuclear periphery in unaffected proliferating HDFs, are
found in the nuclear interior in proliferating laminopa-
thy cells, mimicking their position in non-proliferating
control cells [41,43]. One other study has observed mis-
localization of chromosome 13 in cells from a patient
with a E161K mutation in LMNA [44]. Others have also
shown that heterochromatin is disorganized in HGPS
cells [20,45,46], implying that lamin A is important in
chromatin organization and chromosome territory loca-
tion in interphase nuclei, both of which are perturbed in
laminopathy cells. Furthermore, we have recently
demonstrated that normal human primary fibroblasts
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respond to removal of serum by rapidly repositioning
specific chromosomes within interphase nuclei and that
this movement requires nuclear myosin 1b (NM1b)
[42]. NM1b is now being considered as a component of
a nuclear motor system that can move chromatin
around interphase nuclei [47-50]. It has also been found
to be a lamin A binding partner [51].
In this study we have analyzed chromosome position-
ing in nuclei derived from primary HGPS fibroblasts
and found that chromosome positioning in proliferating
HGPS cells mimics that of control quiescent (serum-
starved) fibroblasts. By treating cells in vitro with a FTI
alone and in combination with a GGTI we re-estab-
lished a nuclear distribution of specific chromosomes in
proliferating HGPS cells that is found in control prolif-
erating fibroblasts. The treatment also restored the
response to serum removal in the cell population so
that chromosomes became relocated within 15 minutes
of serum removal, as they would in control cells.
Furthermore, we found that the nuclear distribution of
NM1b was aberrant in proliferating HGPS cells but
after FTI treatment it was redistributed and restored to
a similar distribution as seen in control proliferating
fibroblasts. Thus, in HGPS cells FTI treatment restores
normal chromosome positioning, the rapid relocation of
whole chromosomes in response to low serum and the
distribution of NM1b. Therefore, by preventing the far-
nesylation of progerin in HGPS cells, chromosomes
behave correctly, possibly due to the correct organiza-
tion of NM1b. This indicates that lamin A is involved in
regulation of chromosome behavior through a nuclear
motor structure.
Results
Interphase chromosome locations in HGPS fibroblast
nuclei resemble those of quiescent (serum-starved)
control fibroblasts
We determined the radial positions of three representa-
tive chromosomes in interphase nuclei of HGPS cells;
chromosomes 10, 18 and X. Chromosome 10 is found
in different nuclear positions in proliferating, quiescent
and senescent nuclei [42,43]. Chromosome 18 moves
from the nuclear periphery to the interior when cells
transit from proliferation to a non-proliferative state and
is found in the nuclear interior in proliferating lamino-
pathy cells, including an HGPS cell line [41]. The X
chromosome remains at the nuclear periphery in all cell
cycle states and is located at the periphery in all lamino-
pathy cells analyzed [41] and as such is used as a nega-
tive control for chromosome repositioning.
To position chromosomes by fluorescence in situ
hybridization (FISH) in interphase nuclei, we fixed cells
in methanol:acetic acid (3:1) to produce flattened cyto-
plasm-free nuclei followed by two-dimensional FISH
with specific chromosome paints. More than 50 digital
images were then used in an erosion analysis that cre-
ates five concentric shells of equal area across the
nucleus and the amount of DNA signal (DAPI) and
chromosome paint signal were measured in each shell
[38,39]. To normalize the data, fluorescence intensity of
the chromosome signal was divided by the intensity of
the DNA signal and the data were plotted as histograms,
with the nuclear periphery represented by shell 1 and
the nuclear interior by shell 5. The proliferative status
of the cells is determined by indirect immunofluores-
cence using antibodies to the proliferative marker Ki-67
[52]. Positive signal indicates that the cells are in prolif-
erative interphase whereas cells negative for Ki-67 in
cultures kept in high serum denote senescent cells [53].
Young quiescent cells, that is, serum starved or cells
that have reached confluency, are also negative for anti-
Ki-67.
Figure 1a, d confirms that chromosome 10 occupies
an intermediate location in proliferating control nuclei
(as determined by pKi-67 staining) and a peripheral
location in control quiescent nuclei (Figure 1g, j). Figure
1p, v, a’’ reveals that chromosome 10 is located at or
towards the nuclear periphery in proliferating HGPS
nuclei. Chromosome 18 is located towards the nuclear
periphery in proliferating control cells (Figure 1e) but is
then interior in control quiescent cells (Figure 1k), and
in all three HGPS cell lines (Figure 1q, w, a’’’). Chromo-
some × is found at the nuclear periphery in control pro-
liferating (Figure 1f) and quiescent cells (Figure 1l), as
well as in all three HGPS cell lines (Figure 1r, x, a’’’’).
These relative positions for chromosomes 10 and × have
been confirmed using three-dimensional fixation, laser
scanning confocal microscopy, optical image reconstruc-
tion and measurement in three-dimensions (Figure S1
in Additional file 1).
We have recently shown that chromosomes relocate
very rapidly to new nuclear locations in control prolifer-
ating fibroblasts placed into low serum [42]. When pro-
liferating control fibroblasts (Figure 2a) are placed in
low serum, chromosome 10 moves towards the nuclear
periphery within 15 minutes (Figure 2I:d), chromosome
18 repositions from the nuclear periphery in proliferat-
ing fibroblasts (Figure 2I:g) to the nuclear interior, again
within 15 minutes of incubation in low serum medium
(Figure 2I:j), and chromosome × remains at the nuclear
periphery from 0 minutes to 7 days (Figure 2I:m-r).
When HGPS cells (AG11498) are placed in low serum
there is no significant change in chromosome location
over 7 days; that is, chromosome 10 remains near the
nuclear periphery (Figure 2II:a-f), chromosome 18
remains in the nuclear interior (Figure 2II:g-l) and chro-
mosome × remains at the nuclear periphery (Figure 2II:
m-r).
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FTI treatment restores wild-type interphase chromosome
positions in HGPS cells for at least two passages
FTIs have been used to correct several cellular aberra-
tions in HGPS cells and in whole organisms. It has been
suggested that by blocking farnesylation, certain proteins
can be alternatively modified by geranylgeranylation.
Thus, we employed FTI-277 both separately and simul-
taneously with GGTI-2147 to determine if we could
restore chromosome position to normal in HGPS cells.
An HGPS cell line (AG11498) was treated with 2.5 μM
FTI-277 (Figure 3I:c, g, k) and with 2.5 μM each of FTI-
277 and GGTI together (Figure 3I:d, h, l). The small
amount of DMSO that was used to dissolve the
inhibitors was used as a control (Figure 3I:b, f, j). As
expected, the X chromosome did not change nuclear
position with any of the treatments. However, with FTI-
277 alone and together with GGTI-2147, chromosome
10 became located in an intermediate radial location in
nuclei (Figure 3I:c, d). Chromosome 18 was also reposi-
tioned after treatment with FTI-277 alone and together
with GGTI-2147 from an internal location to a periph-
eral one (Figure 3I:g, h). Chromosome × was not reposi-
tioned after FTI-277 treatment alone nor with FTI-277
and GGTI-2147 together (Figure 3I:k, l). DMSO alone
had no significant effect on chromosome repositioning
(Figure 3I:b, f, j).
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Figure 1 Positions of chromosomes 10, 18 and × in HGPS human dermal fibroblasts. HDFs derived from HGPS patients were subjected to
two-dimensional FISH in order to delineate and analyze the nuclear positions of chromosome 10, 18 and × territories. (a-c, g-i, m-o, s-u, y-a’)
Chromosome territories are shown in green, pKi-67, a proliferation marker, is shown in red and DAPI staining in blue delineating the nuclear
DNA. Scale bar = 10 μm. (d-f, j-l, p-r, v-x, a’-a’’’) Histograms displaying the distribution of chromosome signal for each chromosome analyzed
using erosion analysis. Bars represent percentage mean normalized proportion of chromosome signal for each chromosome, with shell 1 being
located at the nuclear periphery and shell 5 the nuclear interior. Error bars represent standard error of the mean. In control proliferating
fibroblasts chromosome 10 occupies an intermediate nuclear location (a, d) and chromosomes 18 (b, e) and × (c, f) a location at the nuclear
periphery (b, e). In control fibroblasts made quiescent by serum starvation both chromosomes 10 (g, j) and × (i, l) are located at the nuclear
periphery. In the HGPS cells, chromosome 10 (m, p, s, v, y, a’’) and chromosome × (i, l, o, r, u, x, a’’’’) also occupy a peripheral location in nuclei
whilst chromosome 18 (n, q, t, w, z, a’’’) is positioned in the nuclear interior. Unpaired, unequal variances two-tailed students t-tests were
performed to assess statistical differences between the position of chromosome territories in proliferating HGPS fibroblasts and that of control
proliferating and quiescent control cells. Filled-in squares indicate a difference when compared to control proliferating HDFs, filled in circles
indicate a difference when compared to control quiescent HDFs (P < 0.05).
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After the 48 hour treatments the inhibitors were
removed and the cells permitted to go through two
more passages before chromosome positioning was ana-
lyzed again (Figure 3II). The newly corrected chromo-
some positions in the HGPS cells were maintained for
treatment with FTI-277 alone and FTI-277 together
with GGTI-2147.
Chromosomes are rapidly repositioned in FTI-treated
HGPS cells responding to low serum
After the HGPS cells had been treated with FTI-277 we
wished to see if the rapid active chromosome reposition-
ing after serum removal [42] was restored. Indeed, for
all three chromosomes the starting location in prolifer-
ating nuclei was similar to that in the control cells and
(a) (b) (c) (d) (e) (f)
(h) (i) (j) (k) (l)(g)
(m) (n) (o) (p) (q) (r)
I. Control HDFs
II. HGPS HDFs
(a)
(m) (n) (o) (p) (q) (r)
(g) (h) (i) (j) (k) (l)
(b) (c) (d) (e) (f)
Figure 2 Positions of chromosomes 10, 18 and × in HGPS human dermal fibroblasts following serum starvation Proliferating control
and HGPS (AG11498) cells were placed in low serum (0.5%) for 5 minutes, 10 minutes, 15 minutes, 30 minutes and 7 days. The cells
were subjected to two-dimensional FISH and the nuclear location of chromosome 10 (I:a-f, II:a-f,), chromosome 18 (I:g-l, II:g-l,) and the X
chromosome (I:m-r, II:m-r,) assessed by erosion analysis. Unpaired, unequal variances two-tailed students t-tests were performed to assess
statistical differences between the fibroblasts at 0 minutes and the cells placed in low serum. The filled-in squares represent a significant
difference (P < 0.05). Panel I demonstrates that when control fibroblasts are placed in low serum, chromosome 10 moves from an intermediate
position to a peripheral position (I:a-f), chromosome 18 moves from a peripheral position to an interior location (I:g-l) and chromosome ×
remains at the nuclear periphery (I:m-r). These changes in position have been revealed previously [40,42].
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(a) (b) (c) (d)
(e) (f) (g) (h)
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(a) (b) (c) (d)
(h)(g)(f)(e)
(i) (j) (k) (l)
II. After 2 passages
I. 48 hours
Figure 3 Positions of chromosomes 10, 18 and × in HGPS human dermal fibroblasts after FTI treatment (48 hours) and after two
passages. Histograms displaying the normalized nuclear positions of chromosome 10, 18 and × territories in interphase nuclei subjected to
two-dimensional FISH analysis, and determined by erosion analysis, of untreated AG11498 HGPS fibroblasts (I:a, f, k), AG11498 HDFs treated with
equivalent amounts of DMSO used for dissolution of inhibitors (I:b, g, l), AG11498 fibroblasts treated with 2.5 μM FTI-277 (I:c, h, m), AG11498
fibroblasts treated with 2.5 μM GGTI-2147 (I:d, i, n) and AG11498 HDFs treated with a combination of FTI-277 and GGTI-2147 (2.5 μM each) (I:e,
j, o). Shell 1 represents the nuclear periphery and shell 5 the nuclear interior. Error bars indicate the standard error of the mean. Filled-in squares
indicate statistical difference (P < 0.05) for that shell when compared to the equivalent shell of the untreated sample. Panel II displays the
nuclear positioning of cells treated with the inhibitors for 48 hours and then cultured for a further two passages.
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movement from an intermediate location to the periph-
ery and the periphery to interior for chromosomes 10
and 18, respectively, was apparent after just 15 minutes
(Figure 4II:b, f) with no change in the nuclear position
of the X chromosome (Figure 4II:j). The shape of any
aberrant, herniated, invaginated nuclei was also restored
to more smoothened ellipsoid shapes after the 48-hour
treatment with FTI-277 (data not shown).
Distribution of NM1b in progeria cells before and after
FTI treatment
There is evidence that rapid chromosome repositioning
using the serum removal assay is elicited through
nuclear motor activity, probably involving NM1b [42].
We used an antibody to NM1b that we and others have
employed previously [42], and analyzed the nuclear dis-
tribution of this protein in HGPS cells. In control fibro-
blasts, NM1b is distributed homogenously or as fine
punctuate foci throughout the nucleoplasm with a con-
centration at the nuclear periphery and the nucleolus
(Figure 5a) [42]. The distribution of NM1b in HGPS
nuclei is very different to that found in control prolifer-
ating cells, being much more like the distribution
observed in non-proliferating control cells [42]; there is
some nucleolar anti-NM1b staining but, in addition,
NM1b is localized in large aggregates towards the inter-
ior of the nucleus, without any localization at the
nuclear periphery and some weak staining in the nucleo-
plasm (Figure 5b). Most of the proliferating HGPS cells
displayed NM1b as aggregates (85.1%; Figure 5a, Table
1) but when they were treated with FTI-277 for 48
hours, 73.7% of them displayed a normal distribution of
NM1b (Figure 5c, Table 1), while only 18.6% of treated
HGPS cells displayed NM1b aggregates (Table 1).
To determine if the NM1b distribution was different
in HGPS cells that had been made quiescent, serum
starved HGPS fibroblasts were also analyzed using indir-
ect immunofluorescence with the anti-NM1b antibody.
The distribution of NM1b in quiescent HGPS cells was
similar to that in control cells made quiescent by serum
starvation (Figure 6a), but also to that in proliferating
HGPS cells (Figure 6c), which also had some aggregates
of NM1b staining. In control cells that have been made
quiescent and re-stimulated, the NM1b distribution
returned to a proliferating-type distribution only 24 to
36 hours after the re-addition of serum [42]. Serum-
starved HGPS cells (7 days) were re-stimulated with
serum and samples taken at 24, 36 and 48 hours (Figure
6). In HGPS cells there was no significant difference in
NM1b distribution (aggregates) in proliferating cells
(85.1%; Figure 6a), in quiescent cells (77.3%; Figure 6c)
or in cells re-stimulated with serum and fixed after 24
hours (71.9%; Figure 6e), 36 hours (83.3%; Figure 6g)
and 48 hours (76.4%; Figure 6i). These data are given in
Table 1 and demonstrate that the cells were not respond-
ing to growth factor cues with respect to NM1b, as
occurs in control cells. However, if HGPS cells are trea-
ted with FTI and GGTI together for 48 hours, the distri-
bution of NM1b becomes very similar to control cells,
with more staining throughout the nucleoplasm and a
concentration at the nuclear periphery and nucleolus
(Figure 7a, Table 2). When the treated HGPS cells are
made quiescent for 7 days, the distribution of NM1b in
these cells is typical for a non-proliferating control cul-
ture, with large aggregates of NM1b. When quiescent
cultures of HGPS cells treated with FTIs were re-stimu-
lated by the re-addition of serum, the cells showed a
more normal distribution of NM1b, with nucleoplasmic,
nucleolar and nuclear rim staining. We observed
increases in the normal distribution of NM1b from 2.1%
in quiescent HGPS cells to 35% at 24 hours after re-sti-
mulation (Figure 7e, Table 2), 51.6% at 36 hours (Figure
7g, Table 2) and 64% by 48 hours (Figure 7i, Table 2).
This implies that the cells were able to respond to growth
factors after the FTI treatment and re-position chromo-
somes using a nuclear motor activity that, in a further
experiment, was blocked by the nuclear myosin inhibitor
BDM (2,3-butanedione-2-monoxime; Figure S2 in Addi-
tional file 1), showing that we restored functional motor
activity in HGPS cells for chromosome relocation.
Discussion
The HGPS cells in this study all have a cryptic splice
site (G608G) that results in the accumulation of a toxic
farnesylated lamin A termed progerin. We have pre-
viously shown that chromosome positioning is altered in
a number of primary fibroblast lines derived from lami-
nopathy patients [41], with the positioning of chromo-
somes 13 and 18 within the nuclear interior and not
towards the nuclear periphery, as observed in control
cells. The positioning of these chromosomes in prolifer-
ating laminopathy cells is similar to that in non-prolifer-
ating control cells, given that smaller chromosomes are
found in the nuclear interior in the latter [41]. By exam-
ining the nuclear position of chromosome 10, which is
located within different nuclear compartments in serum
starved quiescent cells and senescent cells [42,43], we
were able to determine that the position of chromosome
10 shown in this study in proliferating HGPS cells was
as it would be in control quiescent cells. Goldman and
colleagues [54] have shown that A-type lamins are
involved intimately with genome organization since cells
in which lamin B1 has been knocked down form nuclear
blebs that specifically contain only A-type lamins. Inter-
estingly, gene-rich regions of the genome are found in
these blebbed areas, implying that changing the lamina
structure and its properties directly affects genome
behavior.
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(a) (b)
(f)
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(c)
(l)
(h)
(d)
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(e) (f) (g) (h)
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I. HGPS HGDFs
II. HGPS HDFs treated with FTIs
Figure 4 Positions of chromosomes 10, 18 and × in HGPS human dermal fibroblasts after FTI treatment following incubation in low
serum. Control fibroblasts and HGPS (AG11513) cells treated with both FTI-277 and GGTI-2147 were placed in low serum, fixed and subjected to
two-dimensional FISH and erosion analysis, with shell 1 representing the nuclear periphery and shell 5 the nuclear interior. The histograms
display the positions of chromosomes 10, 18 and × in interphase nuclei after 0 (a, e, i), 15 (b, f, j), 30 (c, g, k) minutes and 7 days (d, h, l)
following serum withdrawal. Error bars indicate the standard error of the mean. Filled-in squares indicate statistical difference (P < 0.05) for that
shell when compared to the equivalent shell for 0 minute sample. The nuclear repositioning of chromosomes 10 and 18 after serum removal
[42] was restored in the FTI-treated HGPS cells.
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Recently, we demonstrated that chromosomes become
relocated within interphase nuclei very rapidly after cells
are placed in low serum [42]. We repeated this assay
with HGPS cells. Since the chromosomes are already
positioned in the nuclear locations they would be in in
quiescent control cells, we recorded no significant
change. We treated the HGPS cells with a FTI
separately and in combination with a GGTI to preclude
the inhibition of farnesylation being compensated for by
the geranylation of the mutant lamin A. FTI treatment
alone or in combination with GGTI resulted in both
chromosomes 10 and 18 being relocated to the correct
location as seen in control cells-that is, chromosome 10
in an intermediate location and chromosome 18 at the
nuclear periphery. The chromosomes maintained these
positions even after the HGPS cells had gone through
two passages without the inhibitor. This reorganization
of the genome means that chromosome territories have
moved in various directions-for example, some moved
away from the nuclear periphery whereas others moved
towards it, possibly forming anchorage sites at the
nuclear lamina [55].
We have already demonstrated that chromosome
movement and relocation after serum removal is active,
rapid and elicited through nuclear motor activity invol-
ving nuclear actin and myosins, such as NM1b [42].
Staining of proliferating HGPS cells with a commercial
antibody against NM1b showed that NM1b was predo-
minantly in large aggregates. However, when the HGPS
cells were treated with a FTI alone or together with a
GGTI, the nuclear distribution of NM1b became more
like that in proliferating control cells, nucleoplasmic
with prominent staining at the nucleolus and nuclear
envelope. If NM1b is a component of a nuclear motor
complex that is involved in moving chromosomes
around, then its distribution and activity appear to be
restored in HGPS cells treated with the FTI. This was
confirmed in an experiment using BDM to block
nuclear myosin activity in FTI-treated HGPS cells. After
the BDM treatment chromosome 10 did not relocate to
the nuclear periphery as it did in HGPS cells treated
with the FTI alone. Nuclear motors are also involved in
other nuclear activities, such as transcription and chro-
matin remodeling (reviewed in [56]), which may also be
improved by FTI treatment in HGPS cells due to the
reinstatement of NM1b. However, not be being able to
move chromosomes around in the nucleus would have
major implications for cellular differentiation and tissue
(a) (b) (c)
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proliferating cells proliferating cells
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proliferating cells
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treated with
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Figure 5 Nuclear myosin 1b staining in control fibroblasts and
HGPS fibroblasts before and after FTI treatment. NM1b is a
component of the nuclear motor complex that is involved in
chromosome movement. Control and HGPS (AG11498) fibroblasts
(untreated and treated with FTI and GGTI together) were fixed with
1:1 methanol:acetone and subjected to dual indirect
immunofluorescence with commercial rabbit anti-NM1b antibody
(a-c) and a mouse anti-pKi67 (to reveal proliferating cells) (d-f).
Secondary antibodies were a donkey anti-mouse antibody
conjugated to FITC and a swine anti-rabbit antibody conjugated to
TRITC. (a) In proliferating control fibroblasts the distribution of NM1b
is at the nuclear periphery, in the nucleolus and throughout the
nucleoplasm in a fine punctate distribution. (b) In proliferating HGPS
fibroblasts slight nucleoplasmic anti-NM1b staining is apparent but
staining is mainly distributed as large aggregates near the nucleoli.
(c) When HGPS cells were treated with FTI and GGTI together, the
distribution of NM1b was restored to the nuclear periphery and
throughout the nucleoplasm, although there were still large
aggregates present. Scale bar = 10 μm.
Table 1 Distribution of NM1b in HGPS cells
Proliferating HGPS cells 0 hours (quiescent HGPS cells) 24 hours 36 hours 48 hours
Nucleolar + rim + nucleoplasmic 5.8 ± 3.0 0.8 ± 2.0 2.7 ± 6.24 3.1 ± 3.06 10.4 ± 3.05
Nucleolar only 0 ± 0 19.8 ± 6.65 19.7 ± 6.506 8.0 ± 6.08 8.2 ± 3.05
Aggregates 85.1 ± 6.11 77.3 ± 6.55 71.9 ± 5.85 83.3 ± 3.06 76.4 ± 8.96
Rim + nucleoplasmic 5.2 ± 2.51 0 ± 0 2.2 ± 3.06 2.9 ± 4.0 2.2 ± 3.61
Nucleoplasmic 2.9 ± 2.64 1.4 ± 3.51 1.8 ± 3.51 1.8 ± 4.0 1.8 ± 2.64
Dull 0.1 ± 1.53 0.6 ± 0.57 1.7 ± 3.78 0.7 ± 2.0 0.9 ± 2.51
Proliferating HGPS cells were in 15% serum, quiescent HGPS cells were in 0.5% serum for 7 days, and 24, 36 and 48 hours refer to time after the re-addition of
serum. The distribution of NM1b is normally nucleolar + rim + nucleoplasmic in proliferating control cells, while abnormal distributions are nucleolar only,
aggregates, rim + nucleoplasmic, nucleoplasmic only and dull. In control quiescent cells aggregates are the most common distribution observed [42]. Numbers
are percentage values ± standard deviation. The most prominent distribution of NM1b in HGPS cells in high and low serum was in aggregates.
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regeneration in HGPS patients, since whole chromo-
somes and genes are moved and remodeled upon differ-
entiation, correlating with gene expression [57-60]. We
present here the hypothesis that global gene expression
is affected in HGPS cells and that this will be restored
upon normal chromosome localization. Furthermore,
fully processed mature lamin A must be part of this
dynamic process by either binding directly to nuclear
motor proteins or by being part of a required nucleoske-
leton [61] that provides support to the nuclear motor
proteins.
Conclusions
In this study we have demonstrated that proliferating
HGPS cells have chromosome territory positions similar
to quiescent control fibroblasts, as revealed by chromo-
some 10 painting. Using FTI/GGTI treatment to prevent
progerin farnesylation and geranylgeranylation, we were
able to restore normal interphase chromosome position-
ing. More importantly, this treatment restored the rapid
relocalization of chromosomes following serum withdra-
wal. We already have evidence that chromosome move-
ment requires NM1b [42]. Now we demonstrate that
NM1b is distributed aberrantly in proliferating HGPS
cells and that this is only corrected with FTI treatment,
which correlates with the ability of chromosomes to be
able to relocate rapidly. Furthermore, we indicate that
lamin A is involved in chromosome positioning and
behavior, which could be regulated via NM1b as part of
a nuclear motor.
Materials and methods
Cell culture and treatments
Control human HDFs, 2DD [62], and HDFs derived
from three classic HGPS patients (cell lines AG11513,
AG01972C and AG11498, Coricell Repositories) were
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Figure 6 Myosin staining pattern in quiescent HGPS human dermal fibroblasts following re-stimulation. HDFs from HGPS patient
AG11498 were serum-starved for 7 days to induce quiescence. The cells were then re-stimulated with fresh serum and samples were collected
at 0, 24, 36 and 48 hours post-serum restoration. Samples were also collected before serum withdrawal (proliferating cells). The samples were
then fixed with methanol:acetone (1:1) and distribution of NM1b was assessed by performing a dual color indirect immunofluorescence assay for
NM1b (a, c, e, g, i) and pKi67 (b, d, f, h, j). (a, c, e, g, i) The distribution of NM1b in cells before and after re-stimulation of quiescent fibroblasts.
Scale bar = 10 μm.
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Figure 7 Myosin staining pattern in quiescent HGPS human dermal fibroblasts after FTI treatment and following re-stimulation.
AG11498 HDFs treated with FTI-277 were serum starved for 7 days to induce quiescence. The cells were then re-stimulated with fresh serum
and samples were collected at 0, 24, 36 and 48 hours after serum restoration. Samples were also collected before serum withdrawal (proliferating
cells). The samples were then fixed with methanol:acetone (1:1) and distribution of NM1b was assessed by performing an indirect
immunofluorescence assay for NM1b. (a, c, e, g, i) The distribution of NM1b in cells before and after restimulation of quiescent fibroblasts. (b, d,
f, h, j) DAPI staining. Scale bar = 10 μm.
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cultured in 15% FBS in DMEM with passaging twice
every week. The proliferative status of the cell cultures
was assessed by the presence of pKi-67 in cells [53]
using indirect immunofluorescence. In 2DD HDFs the
pKi-67 fraction of cells ranged from 40% to 20%. For
HGPS cells the range was 70% to 2% over time in cul-
ture, demonstrating hyperproliferation in the HGPS
cells, as has been determined before [63]. To elicit a
chromosome movement response, cells were grown in
15% FBS for 2 days and then placed in 0.5% FBS in
DMEM for 5 minutes, 10 minutes, 15 minutes, 30 min-
utes or 7 days. For serum restoration experiments the
cells were cultured in 15% FBS in DMEM for 2 days,
then placed in 0.5% FBS in DMEM for 7 days, which
was replaced with 15% FBS in DMEM for 8 hours, 24
hours, 32 hours and 36 hours.
Treatment with farnesyltransferase I and
geranylgeranyltransferase inhibitors
Inhibitors of farnesylation and prenylation used in this
study were FTI-277 (Calbiochem-Novabiochem, La Jolla,
CA, USA) and GGTI-2147 (Calbiochem-Novabiochem).
Both inhibitors were dissolved in DMSO and stored at
-20°C. HGPS HDFs were seeded at 2 × 105 cells in 10
cm2 tissue culture dishes and then allowed to grow for
at least 2 days in 15% FBS in DMEM. Cells were incu-
bated with 2.5 μM final concentration of FTI-277 and
2.5 μM of GGTI-2147 in 15% FBS in DMEM for 48
hours.
Nuclear myosin inhibitor treatment
Myosin polymerization was inhibited by treating cells
with 10 mM BDM (Calbiochem) for 15 minutes [42].
Two-dimensional FISH
For the two-dimensional FISH assay, HDFs were har-
vested and placed in hypotonic buffer (0.075 M KCl, w/
v) for 15 minutes at room temperature and spun at 400
g. The cells were fixed in 3:1 (v/v) methanol:acetic acid
between five and seven times before being dropped onto
humidified glass microscope slides. After dehydration in
an ethanol row the cells were denatured in 70% forma-
mide, 2× sodium saline citrate buffer (SSC), pH 7, at 70°
C for 2 minutes. Chromosome paints for chromosomes
10, 18 and × were amplified from flow-sorted whole
chromosome templates and labeled with biotin-16-
dUTP by Degenerate OligoPrimer-PCR [64]. We used
200 to 400 μg chromosome paint, 7 μg C0t-1 DNA and
3 μg herring sperm per slide. Hybridization was per-
formed in a humidified chamber for 18 to 24 hours at
37°C. The slides were washed in 50% formamide, 2×
SSC, pH 7, at 45°C for 15 minutes, followed by 0.1×
SSC prewarmed to 60°C for 15 minutes at 45°C. Labeled
hybridized probes were detected with streptavidin-cya-
nine 3 (Amersham Life Science Ltd, GE Healthcare UK
Ltd, Little Chalfont, Buckinghamshire, UK).
Three-dimensional FISH
For the three-dimensional FISH assay, fibroblasts were
washed in PBS and then fixed in 4% paraformaldehyde
(w/v) in PBS for 10 minutes. A permeabilization step
was performed with 0.5% Triton-X100 (v/v) and 0.5%
saponin (w/v) in PBS for 20 minutes. The cells were
then incubated in 20% glycerol in PBS for 30 minutes
prior to being snap-frozen in liquid nitrogen. The cells
were repeatedly frozen and thawed up to five times.
After the freeze-thaw cycles, the cells were washed in
PBS for at least 30 minutes and then incubated in 0.1 N
HCl for 10 minutes. The cells were then washed in 2×
SSC for 15 minutes and incubated in 50% formamide,
2× SSC, pH 7.0, overnight. For denaturation, cells were
incubated at 73 to 76°C in 70% formamide, 2× SSC, pH
7, solution for 3 minutes and then were immediately
transferred to 50% formamide, 2× SSC, pH 7, solution
for 1 minute at the same temperature. All the subse-
quent steps were as for two-dimensional FISH.
Indirect immunofluorescence
To reveal proliferating cells, rabbit anti-Ki-67 antibody
(1:1,500; Dako, Ely, Cambridgeshire, UK). or mouse
anti-pKi67 were incubated with the fixed cells. Second-
ary antibodies employed were swine anti-rabbit
Table 2 Distribution of NM1b in HGPS cells after a 48 hour FTI treatment
Proliferating HGPS cells + FTI 0 hours (quiescent HGPS cells + FTI) 24 hours 36 hours 48 hours
Nucleolar + rim + nucleoplasmic 73.7 ± 7.09 2.1 ± 1.53 35.0 ± 8.18 51.6 ± 3.61 64.0 ± 4.0
Nucleolar only 0 ± 0 19.3 ± 11.32 14.9 ± 2.0 9.8 ± 3.46 8.5 ± 2.64
Aggregates 18.6 ± 6.55 74.2 ± 5.29 45.8 ± 1.53 31.5 ± 4.58 21.8 ± 2.51
Rim + nucleoplasmic 4.8 ± 2.08 0 ± 0 2.5 ± 1.53 3.8 ± 2.08 1.6 ± 0.06
Nucleoplasmic 1.8 ± 2.08 2.9 ± 2.08 1.2 ± 1.15 2.6 ± 3.21 2.1 ± 2.64
Dull 0.9 ± 1.53 1.5 ± 1.53 0.4 ± 1.73 0.5 ± 2.31 1.9 ± 3.79
Distribution was analyzed in FTI-treated HGPS cells in 15% serum (proliferating), 0.5% serum for 7 days (quiescent) and 24, 36 and 48 hours after the re-addition
of serum. The distribution of NM1b in proliferating cells was more like control fibroblasts with a normal distribution of nucleolar + rim + nucleoplasmic that
became like normal quiescent cells with the withdrawal of serum and returned to a more normal distribution for proliferating cells within the expected time
frame (36 to 48 hours) [42]. Numbers are percentage values with ± standard deviation.
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conjugated to either fluorescein isothiocynate (FITC;
1:30; Dako) or tetrarhodamine isothiocynate (TRITC;
1:30; Dako) and donkey anti-mouse conjugated to FITC.
Rabbit anti-NM1b (1:200; Sigma-Aldrich, Poole, Dorset,
UK) was used to reveal NM1b distribution with swine
anti-rabbit conjugated to TRITC (Dako) as the second-
ary antibody.
Image capture and analysis
For two-dimensional FISH analyses, digital grey-scale
images of random nuclei were captured using a Photo-
metrics cooled CCD camera on a Leica fluorescence
microscope (Leitz DMRB) using a Plan Fluotar 100× oil
immersion lens and Digital Scientific Smart Capture
software. The images were run through a simple erosion
script in IPLab spectrum software as described in [38].
DAPI images of the nucleus were outlined and divided
into 5 concentric shells of equal area, the first shell
being most peripheral and the innermost denoting the
interior of the nucleus. The script measures the pixel
intensity of DAPI and the chromosome probe in these
five shells. The probe signal was normalized by dividing
the percentage of the probe by the percentage of DAPI
signal in each shell. Histograms were plotted with stan-
dard error bars representing standard error of the mean.
Simple statistical analyses were performed using the
unpaired two-tailed student’s t-test using Microsoft
excel.
For three-dimensional FISH analyses, images of nuclei
were captured using a Nikon confocal laser scanning
microscope (TE2000-S) equipped with a 60×/1.49 Nikon
Apo oil immersion objective. The microscope was con-
trolled by Nikon confocal microscope C1 (EZ-C1) soft-
ware version 3.00. Stacks of optical sections with an
axial distance of 0.2 μm were collected from 20 random
nuclei. Stacks of 8-bit gray-scale two-dimensional
images were obtained with a pixel dwell of 4.56 and
eight averages were taken for each optical image. The
positioning of chromosomes in relation to the nuclear
periphery was assessed by performing measurements
using Imaris Software (Bitplane Scientific Solutions, Zur-
ich, CH-8048, Switzerland) whereby the distance in
micrometers between the geometric center of each chro-
mosome territory and the nearest nuclear periphery, as
determined by DAPI staining, was measured in three
dimensions. These data were not normalized for size
but when the data were normalized by dividing by the
length of the major axis plus the length of the minor
axis divided by 2 or the length of the major axis alone,
the relative positions of the individual chromosomes in
frequency distributions did not change. Frequency distri-
bution curves were plotted with the distance between
the geometric center of chromosome territory and the
nearest nuclear periphery on the x-axis in actual micro-
meters and the frequency on the y-axis.
Additional material
Additional file 1: Supplementary Figures S1 and S2. Figure S1:
relative nuclear positions of chromosome 10 and × territories in
proliferating HGPS fibroblasts determined using three-dimensional FISH.
The positions of chromosome 10 and × territories in proliferating
AG01972 HDFs (a cell line derived from a HGPS patient) were analyzed
using a three-dimensional FISH assay. Cells were fixed using 4%
paraformaldehyde to maintain the three-dimensional structure and then
subjected to a three-dimensional FISH assay to delineate the area
occupied by a particular chromosome territory. Stacks of optical sections
with an axial distance of 0.2 μm were captured from at least 20 random
nuclei. The distance between the geometric center of the chromosome
territory and the nearest nuclear periphery was then measured. (a, b)
The relative distances of chromosome 10 territories (a) and chromosome
× territories (b) from the nearest nuclear periphery in proliferating HGPS
fibroblasts (red line) are shown and compared to relative distances of
chromosome 10 (a) and × (b) territories in control proliferating (blue
dashed line), quiescent (green dashed line) and senescent (orange
dashed line) HDFs. Figure S2: there is no active chromosome movement
in FTI-treated HGPS cells after inhibition of nuclear myosin using BDM.
The HGPS cell line AG11498 was grown in the presence of a FTI for 48
hours and was either left in 15% FBS (red bars), placed in 0.5% serum
(blue bars) for 15 minutes or placed in low serum for 15 minutes with a
15 minute incubation in BDM to inhibit myosin activity (green bars). Cells
were fixed for and subjected to two-dimensional FISH using a whole
chromosome painting probe for chromosome 10. Images of pKi-67
positive cells were collected and analyzed by the bespoke erosion script
[39]. A 48-hour FTI treatment restored the response to serum removal in
HGPS cells, with chromosome 10 movement towards the nuclear
periphery. This movement of chromosome 10 in FTI-treated HGPS cells
was inhibited by treatment with BDM, which affects the polymerization
and activity of nuclear myosin.
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